PRECeDe 先导试验:糖尿病孕妇择期剖宫产前产前皮质类固醇预防新生儿呼吸窘迫的可行性随机试验
PRECeDe 先导试验旨在评估在多中心随机对照试验(RCT)中,对孕前糖尿病(PGDM)或妊娠期糖尿病(GDM)孕妇在择期剖宫产(CS)前 7 天内给予产前皮质类固醇预防新生儿呼吸系统疾病 efficacy 的可行性。该三盲、平行组、安慰剂对照先导 RCT 在澳大利亚墨尔本单中心三级妇产医院开展,纳入孕 35+0 至 38+6 周计划剖宫产孕妇,随机接受倍他米松 11.4 mg 或生理盐水安慰剂两次注射(间隔 24 小时)。537 名合格孕妇中 182 名被接洽,47 名(26%)被招募,22 名分配至倍他米松组、25 名分配至安慰剂组,未发生与参与相关的严重不良事件。结论认为开展三盲、安慰剂对照 RCT 评估产前皮质类固醇预防 PGDM 或 GDM 孕妇择期剖宫产婴儿呼吸系统疾病是可行的。
要点
- PRECeDe 先导试验为三盲、平行组、安慰剂对照先导 RCT,在澳大利亚墨尔本单中心三级妇产医院开展。
- 纳入孕 35+0 至 38+6 周计划剖宫产的 PGDM(1 型或 2 型糖尿病)或 GDM 孕妇。
- 537 名合格孕妇中 182 名被接洽,47 名(26%)被招募;倍他米松组 22 名,安慰剂组 25 名。
核心结论
- 开展三盲、安慰剂对照 RCT 评估产前皮质类固醇预防 PGDM 或 GDM 孕妇择期剖宫产婴儿呼吸系统疾病是可行的。
研究设计与样本
- 三盲、平行组、安慰剂对照先导 RCT,在澳大利亚墨尔本单中心三级妇产医院开展。
- 纳入孕 35+0 至 38+6 周计划剖宫产的 PGDM(1 型或 2 型糖尿病)或 GDM 孕妇。
- 合格参与者随机接受倍他米松 11.4 mg 或生理盐水安慰剂两次注射,间隔 24 小时,在剖宫产前 7 天内进行。
- 主要结局指标为同意并随机化的合格孕妇比例。
- 试验注册号:澳大利亚和新西兰临床试验注册处 ACTRN12619001475134。
主要发现
- 537 名合格孕妇中 182 名被接洽,47 名(26%)被招募。
- 47 名被招募者中 22 名分配至倍他米松组,25 名分配至安慰剂组。
- 未发生与参与相关的严重不良事件。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The PRECeDe Pilot Trial was designed to determine the feasibility of undertaking a multicentre, randomised controlled trial (RCT) to assess the efficacy of antenatal corticosteroids administration within 7 days before elective caesarean section (CS) in women with pre-gestational diabetes (PGDM) or gestational diabetes (GDM). DESIGN: Triple blind, parallel group, placebo-controlled, pilot RCT. SETTING: Single-centre tertiary maternity hospital in Melbourne, Australia. POPULATION: Pregnant women with PGDM (type 1 or type 2 diabetes) or GDM booked for a planned CS scheduled between 35+0 and 38+6 weeks of gestation. METHODS: Eligible participants were randomised to receive two injections of either betamethasone 11.4 mg or normal saline placebo, 24 hours apart within 7 days before CS scheduled between 35+0 and 38+6 weeks of gestation. MAIN OUTCOME MEASURE: The proportion of eligible women who consented and were randomised. TRIAL REGISTRATION: Australian and New Zealand Clinical Trials Registry ACTRN12619001475134. RESULTS: Of 537 women eligible, 182 were approached and 47 (26%) were recruited. Of these, 22 were allocated to the betamethasone group and 25 were allocated to the placebo group. There were no serious adverse events related to participation. CONCLUSION: It is feasible to undertake a triple-blind, placebo-controlled RCT investigating the efficacy of antenatal corticosteroids in preventing respiratory morbidity in infants of women with PGDM or GDM who are undergoing an elective CS between 35+0 and 38+6 weeks.
引用
- Said JM, Karahalios A, Yates CJ, et al. PRECeDe Pilot: Prevention of neonatal respiratory distress with antenatal corticosteroids before elective caesarean section in women with diabetes - a feasibility randomised trial. BJOG. 2023. PMID: 37186126. doi:10.1111/1471-0528.17513
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。